Redeye provides an update following Guard Therapeutics’ announcement of new encouraging results from...
Redeye provides its initial comments on Xspray following last night’s press release confirming a Com...
Redeye takes a positive stance towards Addnode’s acquisition of SolidCAD.
* Q3'25e organic sales growth of 28% y-o-y * We lower EBITDA on customer mix * FVR of SEK 30-45 reit...
Flexion’s shares are down more than 15% following a report by the newspaper "Affärsvärlden" about a ...
Redeye comments on Invisio’s preliminary announcement of Q3-results which were lower than expected o...
Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivota...
* Report out on 17 October * Q3e sales of SEK 50m, +23% y-o-y, EBIT SEK 16m (9m) * Q3 rebound expect...
Redeye provides a preview of SSH’s Q3 results, set to be released on 23 October.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q3 2025 amounte...
Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its comple...
Alisa Bank announced a collaboration with Nordea, to provide financing services for its entrepreneur...
Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Design...
Redeye updates its estimates and valuation after Mendus’ clinical strategy update.
In a preliminary release ahead of its full report on 24 October 2025, AVTECH announced Q3 2025 net s...
Redeye endorses the news that Egetis has secured cSEK183m in a directed issue and give our initial t...
Redeye kommenterar nedläggningen av ”Project Baxter”, som vi tror var rätt beslut givet förutsättnin...
Redeye comments on the termination of “Project Baxter”, which we believe was the right decision give...
Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to U...
Redeye comments on Mendus announcing a clinical strategy update, communicating its aim to address br...
